Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leptin and Insulin Sensitizer for HAART-Induced Metabolic Syndrome
NCT00362440Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Aug 2006
- Primary completion
- May 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in HIV-associated lipodystrophy syndrome (HALS) and metabolic syndrome comparing Leptin + Pioglitazone/Metformin with Placebo + Pioglitazone/Metformin (2 arms). Primary endpoint: Insulin Resistance (HOMA Index) at 3 months. Started Aug 2006; status: completed.
02
Drugs
leptin
03
Conditions
HIV-associated lipodystrophy syndrome (HALS)metabolic syndrome
Beyond the preview
Go deeper on NCT00362440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362440.